These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19461882)

  • 1. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase.
    Narvaiza I; Linfesty DC; Greener BN; Hakata Y; Pintel DJ; Logue E; Landau NR; Weitzman MD
    PLoS Pathog; 2009 May; 5(5):e1000439. PubMed ID: 19461882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities.
    Bulliard Y; Narvaiza I; Bertero A; Peddi S; Röhrig UF; Ortiz M; Zoete V; Castro-Díaz N; Turelli P; Telenti A; Michielin O; Weitzman MD; Trono D
    J Virol; 2011 Feb; 85(4):1765-76. PubMed ID: 21123384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms.
    Thielen BK; McNevin JP; McElrath MJ; Hunt BV; Klein KC; Lingappa JR
    J Biol Chem; 2010 Sep; 285(36):27753-66. PubMed ID: 20615867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional domain organization of human APOBEC3G.
    Gooch BD; Cullen BR
    Virology; 2008 Sep; 379(1):118-24. PubMed ID: 18639915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A DNA sequence recognition loop on APOBEC3A controls substrate specificity.
    Logue EC; Bloch N; Dhuey E; Zhang R; Cao P; Herate C; Chauveau L; Hubbard SR; Landau NR
    PLoS One; 2014; 9(5):e97062. PubMed ID: 24827831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity.
    Goila-Gaur R; Khan MA; Miyagi E; Kao S; Strebel K
    Retrovirology; 2007 Aug; 4():61. PubMed ID: 17727729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
    Chen H; Lilley CE; Yu Q; Lee DV; Chou J; Narvaiza I; Landau NR; Weitzman MD
    Curr Biol; 2006 Mar; 16(5):480-5. PubMed ID: 16527742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains.
    Hakata Y; Landau NR
    J Biol Chem; 2006 Dec; 281(48):36624-31. PubMed ID: 17020885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G.
    Henry M; Guétard D; Suspène R; Rusniok C; Wain-Hobson S; Vartanian JP
    PLoS One; 2009; 4(1):e4277. PubMed ID: 19169351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the primate APOBEC3A cytidine deaminase gene and identification of related coding regions.
    Henry M; Terzian C; Peeters M; Wain-Hobson S; Vartanian JP
    PLoS One; 2012; 7(1):e30036. PubMed ID: 22272271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.
    Stavrou S; Crawford D; Blouch K; Browne EP; Kohli RM; Ross SR
    PLoS Pathog; 2014 May; 10(5):e1004145. PubMed ID: 24851906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural determinants of human APOBEC3A enzymatic and nucleic acid binding properties.
    Mitra M; Hercík K; Byeon IJ; Ahn J; Hill S; Hinchee-Rodriguez K; Singer D; Byeon CH; Charlton LM; Nam G; Heidecker G; Gronenborn AM; Levin JG
    Nucleic Acids Res; 2014 Jan; 42(2):1095-110. PubMed ID: 24163103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains.
    Bogerd HP; Wiegand HL; Doehle BP; Cullen BR
    Virology; 2007 Aug; 364(2):486-93. PubMed ID: 17434555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
    Pautasso S; Galitska G; Dell'Oste V; Biolatti M; Cagliani R; Forni D; De Andrea M; Gariglio M; Sironi M; Landolfo S
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A chimeric human APOBEC3A protein with a three amino acid insertion confers differential HIV-1 and adeno-associated virus restriction.
    Wang Y; Wang Z; Pramanik A; Santiago ML; Qiu J; Stephens EB
    Virology; 2016 Nov; 498():149-163. PubMed ID: 27584592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock proteins stimulate APOBEC-3-mediated cytidine deamination in the hepatitis B virus.
    Chen Z; Eggerman TL; Bocharov AV; Baranova IN; Vishnyakova TG; Kurlander R; Patterson AP
    J Biol Chem; 2017 Aug; 292(32):13459-13479. PubMed ID: 28637869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction with the CCT chaperonin complex limits APOBEC3A cytidine deaminase cytotoxicity.
    Green AM; DeWeerd RA; O'Leary DR; Hansen AR; Hayer KE; Kulej K; Dineen AS; Szeto JH; Garcia BA; Weitzman MD
    EMBO Rep; 2021 Sep; 22(9):e52145. PubMed ID: 34347354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC3A is a prominent cytidine deaminase in breast cancer.
    Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
    PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association.
    Niewiadomska AM; Tian C; Tan L; Wang T; Sarkis PT; Yu XF
    J Virol; 2007 Sep; 81(17):9577-83. PubMed ID: 17582006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1.
    Ooms M; Krikoni A; Kress AK; Simon V; Münk C
    J Virol; 2012 Jun; 86(11):6097-108. PubMed ID: 22457529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.